Contribution of bone microenvironment to leukemogenesis and leukemia progression

Area of Science:

• Hematology
• Oncology
• Cancer Biology

Background:

• The tumor microenvironment, particularly the bone marrow (BM), plays a critical role in cancer progression and treatment resistance.
• The BM provides a supportive niche for leukemogenesis through growth factors, cytokines, and stromal cells.
• Leukemic cells and BM stroma promote angiogenesis, a process elevated in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Purpose of the Study:

• To elucidate the role of the bone marrow microenvironment in leukemia progression and treatment resistance.
• To identify key molecular mediators and interactions within the leukemia-associated bone microenvironment.
• To explore the potential of bone microenvironment markers as prognostic indicators in leukemia.

Main Methods:

• Review of existing literature on the bone marrow microenvironment in leukemia.
• Analysis of proangiogenic factors such as vascular endothelial growth factor (VEGF) and angiopoietins.
• Investigation of cell-cell interactions, including the CXCR4-CXCL12 axis, and extracellular matrix influences.

Main Results:

• The bone marrow microenvironment facilitates leukemogenesis and resistance to therapy.
• Proangiogenic factors like VEGF and angiopoietins are crucial mediators in acute leukemia.
• Leukemic blast interactions with stromal cells and the extracellular matrix generate antiapoptotic signals, contributing to minimal residual disease.
• The CXCR4-CXCL12 axis is implicated in leukemia progression and disruption of normal hematopoiesis.

Conclusions:

• The bone marrow microenvironment is a significant contributor to leukemia progression and therapeutic resistance.
• Understanding leukemia-associated bone microenvironment markers may offer prognostic and predictive value.
• Further research into the bone microenvironment is essential for improving leukemia treatment strategies and overcoming resistance.